

# Profile

Sysmex Corporation (“the Company”) got its start in 1968 as TOA Medical Electronics Co., Ltd., a specialist manufacturer of instruments and reagents for the hematology market. Over the ensuing 40 years, the Company expanded its R&D and production functions and evolved into a global, comprehensive supplier in the diagnostics field. Extending its operations beyond hematology, the Company’s operations now span the hemostasis, immunochemistry, clinical chemistry, urinalysis and other segments. To symbolize this ongoing transformation, Sysmex unveiled a completely redesigned corporate logo in October 2008.

Sysmex has developed integrated systems encompassing everything from R&D to production, sales and after-sales support. The Company applies a high degree of specialization and a strong technological orientation in its pursuit of uncompromising excellence in product development and manufacturing. Sysmex has earned a top-class reputation with medical institutions around the world for technological excellence paired with the ability to propose solutions that precisely meet customer needs. The Company has established a particularly strong global leadership position in its core segment of hematology, in which it holds the highest market share worldwide.

---

## Forward-Looking Statements

Statements in this annual report, other than those of historical fact, are forward-looking statements about the future performance of Sysmex that are based on management’s assumptions and beliefs in light of information currently available, and involve both known and unknown risks and uncertainties. Actual events and results may differ materially from those anticipated in these statements.

---

To provide products and services that satisfy the diverse needs of markets around the world, Sysmex maintains a global network of business facilities spanning 42 locations in 26 countries. Through this sales and support network, the Company supplies products and services to customers in more than 150 countries. To grow further, Sysmex aims to develop its business on a global basis, as well as by developing proprietary technologies and aggressively pursuing opportunities to expand its operations through alliances, mergers and acquisitions.

The Company is striving to enhance corporate value by leveraging its extensive business infrastructure to advance beyond diagnosis and treatment, encompassing the broader healthcare spectrum that includes disease prevention and health maintenance. Sysmex is moving into new R&D fields, including hematology diseases, immune diseases, infectious diseases, cancer and diabetes. Through these endeavors, the Company will continue to provide high-value-added products and services that help to improve the quality of life (QOL) of people everywhere.

